Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies

被引：0
作者：
Campbell, R. Keith
Cobble, Michael E.
Reid, Timothy S.
Shomali, Mansur E.
机构：
来源：
JOURNAL OF FAMILY PRACTICE | 2010年 / 59卷 / 09期
关键词：
GLUCAGON-LIKE PEPTIDE-1; BETA-CELL FUNCTION; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; HUMAN GLP-1 ANALOG; INSULIN-SECRETION; GLYCEMIC CONTROL; PARALLEL-GROUP; METFORMIN THERAPY; GLUCOSE-TOLERANCE; CONTROLLED-TRIAL;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S5 / S9
页数：5
相关论文
共 47 条
[1]  
[Anonymous], AM DIAB ASS 68 SCI S
[2]  
Aronne Louis J, 2007, Clin Cornerstone, V8, P29, DOI 10.1016/S1098-3597(07)80026-3
[3]   Deteriorating beta-cell function in type 2 diabetes: a long-term model [J].
Bagust, A ;
Beale, S .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (04) :281-288
[4]   Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes [J].
Brazg, R. ;
Xu, L. ;
Dalla Man, C. ;
Cobelli, C. ;
Thomas, K. ;
Stein, P. P. .
DIABETES OBESITY & METABOLISM, 2007, 9 (02) :186-193
[5]   Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1 [J].
Bulotta, A. ;
Hui, H. ;
Anastasi, E. ;
Bertolotto, C. ;
Boros, L. G. ;
Di Mario, U. ;
Perfetti, R. .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 29 (03) :347-360
[6]   One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].
Bunck, Mathijs C. ;
Diamant, Michaela ;
Corner, Anja ;
Eliasson, Bjorn ;
Malloy, Jaret L. ;
Shaginian, Rimma M. ;
Deng, Wei ;
Kendall, David M. ;
Taskinen, Marja-Riitta ;
Smith, Ulf ;
Yki-Jarvinen, Hannele ;
Heine, Robert J. .
DIABETES CARE, 2009, 32 (05) :762-768
[7]   Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].
Buse, John B. ;
Rosenstock, Julio ;
Sesti, Giorgio ;
Schmidt, Wolfgang E. ;
Montanya, Eduard ;
Brett, Jason H. ;
Zychma, Marcin ;
Blonde, Lawrence .
LANCET, 2009, 374 (9683) :39-47
[8]   Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [J].
Chacra, A. R. ;
Tan, G. H. ;
Apanovitch, A. ;
Ravichandran, S. ;
List, J. ;
Chen, R. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) :1395-1406
[9]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J].
Charbonnel, Bernard ;
Karasik, Avraham ;
Liu, Ji ;
Wu, Mei ;
Meininger, Gary .
DIABETES CARE, 2006, 29 (12) :2638-2643
[10]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
12345